Phaseline

Companies › BlossomHill Therapeutics

BlossomHill Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Jun 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
BH-30236–Phase 1LeukemiaJun 2027
BH-30643
Dual EGFR/HER2 inhibitor
EGFR, HER2Phase 1NSCLC (Advanced Non-small Cell Lung Cancer)Jan 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06501196BH-30236Phase 1LeukemiaOncologyJun 2027
NCT06706076BH-30643Phase 1NSCLC (Advanced Non-small Cell Lung Cancer)OncologyJan 2029

From the company's SEC filings

Cash of $95m on 2026-06-30; operating cash outflow about $90m a year; runway about 13 months at that burn, to Jul 2027

Press releases filed as 8-K in the last year:

Private offerings reported to the SEC (Form D)

Targets

EGFR (1) HER2 (1)

Companies with the same targets

AstraZeneca Shanghai Henlius Biotech Allist Pharmaceuticals Dizal Pharmaceuticals Betta Pharmaceuticals Beijing Biotech Pierre Fabre Medicament Jiangsu Hansoh Pharmaceutical Johnson & Johnson (Janssen) Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.